Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation

20 Mar 2023

• By Michael McCaughan

The US Medicare agency intends to treat all dosage forms of the same active ingredient as a single drug for purposes of its new price negotiation authority. The approach will have implications for product branding and line extension strategies.

CMS is casting a wide net on dosage forms, branding and indications as it prepares for Rx price negotiations. • Source: Shutterstock

The US Medicare agency is casting a very broad net to ensure that all versions of the same active ingredient are included in the price negotiation process, regardless of differences in dosage form, branding, indications, or regulatory pathway.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

24 Apr 2025

• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

23 Apr 2025

• By Leslie Small

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Europe Should Pay Drug Prices More In Line With US, Two Pharma CEOs Argue

23 Apr 2025

• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

Kiji CEO On EU HTA Regulation, Hospital Exemption And The Future Of ATMPs

23 Apr 2025

• By Eliza Slawther

Miguel Forte, CEO of Kiji Therapeutics, tells the Pink Sheet why he is confident in the future of gene therapies, despite the global “turmoil” that is impacting investment in the industry and changes to the EU and US regulatory landscapes.

Brazil’s ANVISA Clarifies Registration Procedures For Biologicals

24 Apr 2025

• By Francesca Bruce

Brazil’s drug regulator has published a new technical note updating guidelines on registration and post-registration procedures for biological products.